Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

Find Clinical Drug Pipeline Developments & Deals by Toolgen

Toolgen
Developments
Full Screen View

Toolgen

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

No Content

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Toolgen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

Details:

The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's TGT-101 & CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.

Lead Product(s): TGT-101

Therapeutic Area: Ophthalmology Product Name: TGT-101

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: mCureX

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 15, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY